This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Printer-Friendly Email Page
Start the program at
the bottom of this page

Slowing Cognitive and Functional Decline in Alzheimer's Disease: Evaluating the Evidence
Release Date: November-16-11
Credit Expiration Date: February-13-13
Medium
This educational activity is designed to meet the needs of consultant and senior care pharmacists.
Credit Hours
1.5 contact hours (0.15 CEU)
Medium
Link - Online
Program Description
NOTE: This activity was presented on November 16, 2011, in conjunction with ASCP's Annual Meeting and Exhibition. Participants who received credit for attending the live presentation on that date are not eligible to receive credit for this online activity.

The burden of AD is well known. In the United States, there are more than 5 million individuals with AD. This number is expected to climb to 7.7 million people by the year 2030. AD is now the sixth leading cause of death in the United States. As the US population ages, dementia syndromes such as AD are growing more prevalent. Roughly 60 to 80% of elderly patients with chronic dementia have AD, a progressive condition that leads to memory loss, personality changes, cognitive dysfunction, and functional impairment. The number of patients with AD continues to grow each year.

Senior care pharmacists play a critical role in ensuring that patients are evaluated, monitored, and treated appropriately. While current therapies cannot halt the disease, active medical management can significantly improve the quality of life for patients with AD and their caregivers and family members. As new evidence regarding optimal treatment approaches for AD continues to emerge, senior care pharmacists require education in order to continue providing care based on current best practices.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Implement strategies to support accurate and early identification of patients with Alzheimer’s disease.
2.
Describe the need for the stage-specific management of patients with Alzheimer’s disease.
3.
Outline the optimal use of pharmacologic and non-pharmacologic approaches in the management of Alzheimer’s disease.
4.
Recommend medication regimens to minimize polypharmacy and medication adverse events in patients who have moderate to severe Alzheimer’s disease.
faculty
Gary Small, MD
Professor of Psychiatry and Biobehavioral Sciences
Arlow-Soloman Professor on Aging
David Geffen School of Medicine at UCLA
Los Angeles, CA

Bradley Williams, PharmD, CGP
Professor of Clinical Pharmacy
Clinical Pharmacy and Pharmaceutical Economics & Policy
University of Southern California
Los Angeles, CA
faculty
It is the policy of the ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Small discloses that he has served on the speaker's bureau for Novartis and Forest Pharmaceuticals, served as a consultant for Lilly and Dakim, is a major stockholder for Dakim, and has received grants and research support and served as a clinical investigator for Pom Wonderful.

Dr. Williams has no relevant financial relationships with any commercial interests to disclose.
Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-116-H01-P, has been assigned 1.5 Contact Hour (0.015 CEU).

Please view and complete the posttest questions and activity evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.

There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported by an educational grant from Forest Research Institute, a subsidiary of Forest Laboratories, Inc.
Certificate Fee

$0.00

Disclaimer
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
Printer-Friendly Email Page
Start Program
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.